Why Akero’s Liver (NASH) Treatment Could Take This Stock Much Higher
Akero Therapeutics has been public for only about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Akero Therapeutics Inc. (NASDAQ: AKRO) has only been public for about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much higher. Wednesday’s jump came from positive results from its midstage trial for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Specifically, the company announced results from a 16-week analysis of secondary and exploratory endpoints in its Phase 2a Balanced study of efruxifermin (EFX), formerly known as AKR-001, in patients with NASH.
A main highlight of the report was that of the 40 treatment responders who had end-of-treatment biopsies, 48% achieved at least a one-stage improvement in fibrosis without worsening of NAFLD activity score (NAS) and 28% achieved at least a two-stage improvement in fibrosis. Additionally, 48% of responders achieved NASH resolution with no worsening of fibrosis.
At the same time, Akero saw improvements in glycemic control and dyslipidemia, as well as weight loss, across all dose groups. Treatment with EFX was reported to be generally well tolerated.
[nativounit]
Management was quick to say that the Balanced study data exceeded expectations and demonstrated the strong potential of EFX to be a foundational monotherapy for the treatment of NASH. Andrew Cheng, M.D., Ph.D., president and CEO of Akero, added, “We look forward to the continued development of efruxifermin and are working diligently to deliver this potentially leading treatment to patients.”
Obviously, these are stellar results for a midstage trial, and they seem to suggest that the potential for EFX as a treatment for NASH could be tremendous. Analysts agreed with this sentiment with a few hiking their targets in response:
- Evercore ISI raised its price target to $80 from $35.
- Canaccord Genuity reiterated a Buy rating and raised its target to $51 from $36.
- H.C. Wainwright reiterated a Buy rating and raised its price target to $45 from $33.
- Jefferies reiterated a Buy rating and raised its target price from $31 to $48.
- JPMorgan reiterated it as Overweight and raised its price target to $41 from $28.
Akero Therapeutics stock gained 34% Wednesday to close at $33.37, but it was last seen at $31.99 on Thursday, within a 52-week range of $10.78 to $35.20. The consensus price target is $34.33.
[recirclink id=716538][wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
